{"id":"clm_1DFB726EC635","entity":"regeneron-pharmaceuticals","predicate":"total_equity","value":"806,024,000 United States dollar","value_json":{"fp":"Q3","fy":2012,"accn":"0001532176-12-000004","form":"10-Q","filed":"2012-10-24","period":"Q3 FY2012","concept":"us-gaap:StockholdersEquity"},"valid_from":"2012-09-30","valid_to":"2012-12-31","published":"2012-10-24","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total equity: 806,024,000 United States dollar\", as of 2012-09-30 (until 2012-12-31). Claim clm_1DFB726EC635, https://asof.is/claim/clm_1DFB726EC635, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217612000004/0001532176-12-000004-index.htm.","url":"https://asof.is/claim/clm_1DFB726EC635","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_B3960C0B2099","supersedes":["clm_9E8EECD34DB3"],"first_seen_at":"2026-11-08T17:08:51.481862+00:00","updated_at":"2026-11-08T17:08:58.955536+00:00","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/872589/000153217612000004/0001532176-12-000004-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2012","published_at":"2012-10-24T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2012, filed 2012-10-24"},"legend":{"dates":"valid_from: when the claim took effect (a period figure: the day its period closed). published: the earliest day a source on the record published it (a filing's filing date, a post's date; null when no source carries one). recorded: the day AsOf first held it. A figure can take effect weeks before it is published.","citation":"citation: how to cite the row (plain: one sentence with the value, its as-of date, the claim id and URL, the day answered and the primary source; url: the claim page; accessed: the day answered). APA and BibTeX forms are on the claim page.","why_not":{},"checked_by":{"sec-filing":"parsed from the SEC filing"}}}